Parkinson S Disease Press Releases

The United States Patent and Trademark Office (USPTO) has issued a patent on NLX-112, a drug candidate developed by Neurolixis for treatment of human movement disorders, notably levodopa-induced dyskinesia in Parkinson's disease.

Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their hemoglobin depletion technology for enriching the red cell proteome, to observe and report sub-forms of α-Synuclein in Parkinson's Disease.

Neurolixis Inc. has been awarded funds by the US Department of Defense to test its drug candidate, NLX-112, in a preclinical model of Machado-Joseph disease (MJD), a rare and disabling inherited movement disorder.

The Neurolixis lead compound, NLX-112, is at the heart of a brain imaging investigation of functionally-active serotonin 5-HT1A receptors in humans. NLX-112, a.k.a.

The US Food and Drug Administration (FDA) gave a positive response to Neurolixis' Investigational New Drug (IND) application for NLX-112.

Neurolixis launched a collaboration with the GALA® laboratory in Castres, France. GALA® is a platform of the Rapsodee/IMT Mines Albi research facility specialized in developing novel drug formulations.

Howard Shifke knows a thing or two about Parkinson's disease. In his book "Fighting Parkinson's...and Winning: A memoir of my recovery from Parkinson's Disease," Shifke recounts the story of his developing Parkinson's, getting diagnosed, and his daily...